Professional tools
Explore videos and downloadable materials to support the recommendations you may make to your patients about OTC analgesics.
Special Report includes case studies, real-world clinical scenarios, guideline recommendations, and OTC analgesics’ efficacy and safety profiles
Keep multimodal analgesia reminders top of mind as you work with patients to create their personal pain management plan.
Gain insight from a multidisciplinary team of experts on topics including coexisting medical conditions, concomitant medications, and patient counseling
Learn what your HCP peers consider, like coexisting medical conditions and drug contraindications, before recommending an OTC analgesic
Use this streamlined list to identify patient conditions and medications that may impact your OTC analgesic recommendation
Teach fellow HCPs the impact of pain on patients & how to help ensure appropriate analgesic choice & use
Understand the mechanism by which ibuprofen may compromise aspirin’s cardiovascular benefits1
See how NSAID inhibition of COX-1 can lead to GI side effects such as ulcers and bleeding2,3-5
See how NSAID inhibition of both COX-1 and COX-2 may affect patients who already have some renal dysfunction6
Get a closer look at the mechanism of acetaminophen metabolism through 3 distinct hepatic pathways7-9
Get perspectives on OA pain management from a primary care physician and a rheumatologist. Viewable in 4 parts
REFERENCES: 1. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817. 2. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008; 118(8):1894-1909. 3. Hirschowitz BI. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Gastroenterol. 1994;2(3):207-223. 4. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137-142. 5. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999;21(6):992-1003. 6. DeMaria AN, Weir MR. Coxibs—beyond the GI tract: Renal and cardiovascular issues. J Pain Symptom Manage. 2003;25(2S):S41-S49. 7. Patten CJ, Thomas PE, Guy RL, et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol. 1993;6(4):511-518. 8. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys. 1989;271(2):270-283. 9. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol. 1993;45(8):1563-1569.